<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To evaluate whether <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> is an independent risk factor for silent <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> (SBI), and to determine the relationship between <z:chebi fb="0" ids="17230">homocysteine</z:chebi> and <z:chebi fb="3" ids="37445">folate</z:chebi> in each type of <z:chebi fb="0" ids="25297">methylenetetrahydrofolate</z:chebi> reductase (MTHFR) polymorphism, in order to identify a way of reducing the risk for SBI </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The authors enrolled 161 patients with SBI and 126 healthy people, checked their fasting <z:chebi fb="0" ids="17230">homocysteine</z:chebi> and <z:chebi fb="3" ids="37445">folate</z:chebi> levels, and analyzed for the MTHFR C677T polymorphism </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: The mean plasma <z:chebi fb="0" ids="17230">homocysteine</z:chebi> level in patients with SBI (12.17 +/- 5.35 micro mol/L) was significantly higher than in <z:mpath ids='MPATH_458'>normal</z:mpath> healthy people (9.37 +/- 4.11 micro mol/L; p &lt; 0.05) </plain></SENT>
<SENT sid="3" pm="."><plain>By subgroup analysis, based on the classification of plasma <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels as high (&gt;or=11.77 micro mol/L), moderate (8.71 to 11.76 micro mol/L), and low (&lt;or=8.70 micro mol/L), the adjusted OR (AOR) of the high group for SBI was significantly greater than that of the low group (AOR, 4.78; 95% CI, 2.45 to 9.33) </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:chebi fb="0" ids="17230">homocysteine</z:chebi> level showed a significant inverse correlation with <z:chebi fb="3" ids="37445">folate</z:chebi> level only in patients with SBI with the MTHFR 677TT genotype (p &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS: This study demonstrates that <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> is an independent risk factor for SBI, and provides the possibility of reducing the risk for SBI in the MTHFR 677TT genotype by <z:chebi fb="3" ids="37445">folate</z:chebi> supplementation </plain></SENT>
</text></document>